**Molecular and Cellular Pathobiology**

**p190RhoGEF (Rgnef) Promotes Colon Carcinoma Tumor Progression via Interaction with Focal Adhesion Kinase**

Hong-Gang Yu, Ju-Ock Nam, Nichol L. G. Miller, Isabelle Tanjoni, Colin Walsh, Lei Shi, Linda Kim, Xiao Lei Chen, Alok Tomar, Ssang-Taek Lim, and David D. Schlaepfer

**Abstract**

Focal adhesion kinase (FAK) functions downstream of integrins and growth factor receptors to promote tumor cell motility and invasion. In colorectal cancer, FAK is activated by amidated gastrin, a protumorigenic hormone. However, it is unclear how FAK receives signals from the gastrin receptor or other G-protein–coupled receptors that can promote cell motility and invasion. The Rho guanine-nucleotide exchange factor p190RhoGEF (Rgnef) binds FAK and facilitates fibroblast focal adhesion formation on fibronectin. Here we report that Rgnef mRNA and protein expression are significantly increased during colorectal tumor progression. In human colon carcinoma cells, Rgnef forms a complex with FAK and upon gastrin stimulation, FAK translocates to newly-forming focal adhesions where it facilitates tyrosine phosphorylation of paxillin. Short hairpin (shRNA)-mediated knockdown of Rgnef or FAK, or pharmacological inhibition of FAK activity, is sufficient to block gastrin-stimulated paxillin phosphorylation, cell motility, and invadopodia formation in a manner dependent upon upstream cholecystokinin-2 receptor expression. Overexpression of the C-terminal region of Rgnef (Rgnef-C, amino acid 1,279–1,582) but not Rgnef-CFAK (amino acid 1,302–1,582 lacking the FAK binding site) disrupted endogenous Rgnef-FAK interaction and prevented paxillin phosphorylation and cell motility stimulated by gastrin. Rgnef-C–expressing cells formed smaller, less invasive tumors with reduced tyrosine phosphorylation of paxillin upon orthotopic implantation, compared with Rgnef-CΔFAK–expressing cells. Our studies identify Rgnef as a novel regulator of colon carcinoma motility and invasion, and they show that a Rgnef–FAK linkage promotes colon carcinoma progression in vivo. *Cancer Res;* 71(2); 360–70. ©2011 AACR.

**Introduction**

Colorectal tumor metastasis results in an overall mortality rate of 33% (1). Elucidation of the molecular mechanisms driving tumor invasion may lead to new therapeutic options. During tumor progression, cells can undergo an epithelial to mesenchymal transition associated with increased cell motility (2). This involves the dissolution of cell–cell contacts and the formation of integrin receptor-mediated cell-substratum sites termed focal adhesions (FA; ref. 3). Tumor progression is associated with increased local tumor cell invasion mediated in part by signals generated at FAs (4, 5). A key protein that localizes to FAs and facilitates tumor cell motility–invasion is focal adhesion kinase (FAK; ref. 6, 7).

FAK is recruited to FAs via interactions with integrin-associated proteins such as talin and paxillin (8). FAK is a cytoplasmic protein tyrosine kinase that is activated by integrin clustering where FAK autophosphorylation at Tyr-397 facilitates the recruitment of Src-family protein-tyrosine kinases into a multiprotein signaling complex (9, 10). Increased paxillin tyrosine phosphorylation by the FAK–Src complex is associated with FA formation and cell movement (11, 12). FAK expression and activity are elevated as a function of tumor progression (13) and FAK signaling promotes tumor metastasis (14).

Activation of the FAK–Src complex can also occur after G-protein–coupled receptor (GPCR) stimulation of cells (15). Gastrin is a circulating peptide hormone triggering increased gastric acid secretion (16). Gastrin also promotes the growth of normal gastric mucosa as well as various gastrointestinal cancers (gastric, pancreatic, colorectal; refs. 17, 18). Gastrin binding to the GPCR cholecystokinin receptor (CCK2R) can initiate intracellular signaling events (19, 20). Tumor-associated gastrin and CCK2R expression are associated with...
malignant characteristics of gastrointestinal tumors (21). How FAK is activated downstream of gastrin-CCKR2 remains undefined.

Current models linking GPCR signaling to FAK involve actin cytoskeletal stress fiber formation, tension generation, and FA formation as key events leading to increased FAK activation (19). This linkage involves RhoA GT-Pases controlled in part by guanine nucleotide exchange factors (GEF) that catalyze the exchange of GDP for GTP on RhoA (22, 23). For GPCR-associated signaling, heterotrimeric Goi binding to p115Rho-GEF facilitates RhoGTPase activation (24). It is the RGS (regulators of G-protein signaling) domain within p115Rho-GEF that connects to GPCRs and is conserved in other GEFs such as PDZ-RhoGEF and LARG (25). Notably, FAK can associate with PDZ-RhoGEF and this connection may influence FA dynamics (26). In addition, FAK can bind to a non-RGS–containing RhoGEF termed Rgnef (p190RhoGEF) that promotes RhoA activation and FA formation downstream of integrins (27, 28). Rgnef can localize to FAs and this is dependent on the FAK-binding region (residues 1,292–1,582) within the Rgnef C-terminal domain. Although overexpression of CCKR2 potentiates gastrin-stimulated FAK activation (29, 30), it remains unknown whether particular GEF interactions with FAK facilitate gastrin-CCK2R stimulated signaling events or colon carcinoma tumor progression.

Herein, we find that Rgnef protein expression becomes elevated during colon tumor progression and that a complex between Rgnef and FAK controls gastrin-stimulated paxillin phosphorylation, cell motility, and matrix degradation. As Rgnef C-terminal domain overexpression prevented orthotopic colon carcinoma tumor growth and local invasion in a FAK binding-dependent manner, our findings establish Rgnef as a novel regulator of FAK signaling downstream of GPCRs involved in promoting tumor progression.

**Materials and Methods**

**Antibodies and reagents**

Antibodies to Hic-5, c-Src, and c-Yes (C-4) were from Santa Cruz Biotechnology. Monoclonal antibody (mAb) to FAK was from Millipore. Paxillin mAb was from BD Biosciences. β-actin mAb was from Sigma. Green fluorescent protein (GFP) mAb was from Covance and polyclonal antibodies to mCherry were from Clontech. FAK Tyr-397 (pY397) and paxillin Tyr-31 (pY31) phosphospecific antibodies were from Invitrogen. Affinity-purified rabbit antibodies to Rgnef were generated using peptides 1,247–1,265 (EDVHLEPHLLIKPDPGEPP, rabbit 3647) and 1,502–1,519 (ERLREGQRM-DVHPENPSTV, rabbit 3659). The antisense primer was 5’-TGAGAATTCTGTTGCCATCATATcagagaTGATGGCAACCAGAATTTCCTTTTTTCT-3’ and the sense primer encompassed then end of the U6 promoter, the shRNA loop (lower case letters), and an added 3’C to generate an XhoI site. The antisense primer was 5’-TCGAGAATTCTGTTGCCATCATATcctttgaATA-TGATGGCAACCAGAATTTC-3’.

**Cell culture**

DLD-1, Caco-2, HCT-116, HT-29, and SW-480 human colorectal carcinoma cells were obtained from American Type Culture Collection. Early passage cells were used for all experiments and they were not reauthenticated. All cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1 mmol/L of nonessential amino acids, 2 mmol/L of glutamine, 100 U/mL penicillin and 100 μg/mL streptomycin. DLD-1 cells expressing Scr, anti-FAK, anti-paxillin, anti-c-Src, or anti-Rgnef shRNA, and GFP–Rgnef over-expressing cells were obtained by fluorescence activated cell sorting (FACS) and maintained as pool populations. DLD-1 mCherry, DLD-1 mCherry-Rgnef-C, and DLD-1 mCherry-Rgnef-CΔFAK were obtained by FACS. DLD-1 cells contain mutations in K-Ras and p53 (33).

**Cell lysis, immunoprecipitation, and blotting**

Subconfluent cells were starved overnight (serum-free media) and dimethyl sulfoxide (DMSO) or gastrin (200 nmol/L) were added for the indicated time. Cells were solubilized in ice-cold modified protein lysis buffer containing 1% Triton X-100, 0.5% sodium deoxycholate and 0.1% SDS (34). For immunoprecipitations, antibodies (2.5 μg) were incubated with lysates (500 to 1 mg total protein) at 4°C and collected by bead binding (Invitrogen). Proteins were resolved by SDS-PAGE and membrane immunoblotting performed as described (34). Relative protein expression levels and phospho-specific antibody reactivity were quantified using Image J (v1.43).

**Immunofluorescent staining**

Cells were plated at low density onto 1% gelatin-coated glass coverslips until colonies of approximately 30 cells were formed (48–60 hours). After overnight serum starvation, DMSO or gastrin (200 nmol/L) was added for 45 to 60 minutes. Cells were fixed (3.7% paraformaldehyde in PBS, 10 minutes), permeabilized (0.1% Triton X-100 in PBS, 10 minutes) and coverslips were blocked with 2% bovine serum albumin in PBS for 1 hour. For staining, coverslips were incubated with anti-FAK or anti-paxillin antibodies at 4°C overnight and visualized using either fluorescein isothiocyanate-conjugated (FITC) goat anti-mouse IgG, Alexa-fluor-488 goat anti-mouse IgG, Texas Red–phalloidin, and nuclei stained with 4’,6-diamidino-
2-phenylindole (DAPI). Images were acquired using a spinning disk confocal microscope (IX81, Olympus) and monochrome camera (ORCA ER, Hamamatsu).

**Anti-Rgnef tumor staining**

Micro-array slides (US Biomax; CO1002, CO701, CO2085a) with colon tumor (with clinical stage and pathology grade) and adjacent normal tissue sections were incubated at 60°C for 90 minutes to facilitate tissue core adhesion, paraffin was removed with xylene and tissue cores were rehydrated. Antigen retrieval was performed by boiling in 10 mmol/L of sodium citrate, pH 6.0 for 5 minutes. Slides were washed, endogenous peroxidase activity was quenched with 0.3% hydrogen peroxide (10 minutes), and tissue cores blocked for 45 minutes (block buffer: PBS with 5% normal goat serum and 0.3% Triton X-100). Affinity-purified rabbit polyclonal Rgnef antibodies (rabbit 1397) were diluted 1:150 in block buffer and 0.3% Triton X-100). Affinity-purified rabbit polyclonal Rgnef antibodies (rabbit 1397) were diluted 1:150 in block buffer, incubated overnight at 4°C, and followed by biotinylated goat anti-rabbit IgG (Vector Labs) at 1:300 for 30 minutes. Rgnef staining was visualized using the Vectastain ABC Elite reagent, 3,3-diaminobenzidine tetrahydrochloride peroxidase substrate, and counterstained with Hematoxylin QS (Vector Labs). Individual tissue cores were scored blind and recorded as negative (−), +/−, +, ++, +++ to designate levels of Rgnef staining.

**Colony scattering-motility assay**

Cells were plated at low density onto 1% gelatin-coated glass coverslips until colonies of approximately 30 cells were formed (48–60 hours). After overnight serum starvation, DMSO or gastrin (200 nmol/L) was added, and after 18 hours, cell colonies (>200 per experiment) were evaluated by phase-contrast microscopy. A colony with less than 50% cell–cell contacts was considered scattered. At least 3 independent experiments were performed.

*In situ* zymography. Oregon green 488-conjugated gelatin (Invitrogen) degradation assays performed as described (35) with minor modifications. Briefly, after gelatin cross-linking and quenching–washing of glass slides, cells were plated in DMEM containing 10% FBS with DMSO or gastrin (200 nmol/L) and incubated at 37°C for 18 hours followed by 3.7% paraformaldehyde fixation. Phases and fluorescent images of cells were evaluated for areas of degradation. Positive values are presented as percent of total cells (>200 cells per experimental condition) with at least 1 degradation patch (independent of size).

**Orthotopic colorectal tumor growth**

6-week-old female nude (nu/nu) mice (Harlan Labs) were housed in pathogen-free conditions under approved institutional animal care and use protocols. One million DLD-1 cells expressing mCherry, mCherry-Rgnef-C, or mCherry-Rgnef-CAFak were mixed with growth-factor-reduced Matrigel (BD Biosciences) and injected (in 10 μL) submucosally into the distal posterior rectal wall as described (36). After 24 days, the peritoneal cavity was opened and fluorescent tumors visualized (OVI100, Olympus). Tumors were resected, weighed, and the posterior colon area was imaged a second time to determine the extent of local tumor invasion. Tumors were divided in half and either homogenized in protein lysis buffer for immunoblotting or imbedded in Optimal Cutting Temperature compound (Tissue Tek), frozen in liquid nitrogen, thin sectioned (7 μmol/L), and mounted onto glass slides. Sections were stained with hematoxylin and eosin (H&E) and images acquired at ×10 with a color camera (Infinity1-3C, Lumenera). Detection of mCherry fluorescence and anti-desmin (Thermo Scientific) staining was performed by methods as mentioned previously. Multicolor images were sequentially captured at ×10 (UPLFL objective, L3 NA; Olympus) pseudocolored, overlaid, and merged using Photoshop CS3 (Adobe).

**Statistical methods**

For cell culture experiments, mean values and SD of at least triplicate experimental points were calculated. Student’s *t* test was used to compare mean value differences. For tumor experiments, differences between groups were determined using 1-way ANOVA with Tukey post hoc test. Differences between pairs of data were determined using an unpaired 2-tailed student’s *t* test. The distribution (negative to ++++) of Rgnef tumor staining was evaluated using Pearson’s chi-square test. Statistical analyses were performed using GraphPad Prism (version 5.0b).

**Results**

**Elevated expression of Rgnef in colon cancer**

Rgnef (p190RhoGEF) is a ubiquitously-expressed protein consisting of a central Dbl/pleckstrin-homology catalytic region associated with GEF activity (37; Fig. 1A). To determine if Rgnef expression is altered in colon cancer, semiquantitative reverse transcriptase PCR was performed using mRNA samples obtained from colorectal tumor and paired normal colorectal tissue (Supplementary Fig. 1A). Surprisingly, an Rgnef-specific band was detected in only 25% (4 of 16) of cancerous tissues. These positive samples were tumor grade 3 to 4 whereas Rgnef was below the level of experimental detection in fourteen grade 1 to 2 tumors and sixteen normal tissue samples (Supplementary Fig. 1A). To extend these observations, polyclonal anti-peptide antibodies were generated to Rgnef (Fig. 1A), affinity-purified, and verified to be specific for Rgnef detection (Supplementary Figs. 1B and C). Anti-Rgnef staining of colon cancer tissue microarray slides revealed a number of samples with strong (++ to ++++) Rgnef staining (Fig. 1B). In the analysis of 308 tissue sections ranging from normal colon to tumor grade 4, moderately increased Rgnef staining was detected in tumor grade 1 to 2 compared with normal (*P* < 0.03) samples, and further elevated Rgnef levels were detected in tumor grade 3 to 4 compared with grade 1 to 2 (*P* < 0.0001) samples (Table 1). Together, these results support the conclusion that Rgnef mRNA and protein expression increases as a function of colon cancer tumor progression.

**FAK activation is important for gastrin-stimulated paxillin tyrosine phosphorylation and cell scattering**

Immunoblotting analyses revealed ubiquitous Rgnef expression in DLD-1, Caco-2, HCT-116, HT-29, and SW-
480 colon carcinoma tumor cells (Fig. 2A). FAK was expressed in all cells except SW-480 wherein FAK-related Pyk2 kinase expression was detected. Previous studies showed that gastrin enhanced FAK and paxillin tyrosine phosphorylation in Colo320 colon carcinoma cells overexpressing the CCK2R receptor (29). As gastrin stimulates signaling within DLD-1 cells (38), we tested whether gastrin enhanced FAK and paxillin tyrosine phosphorylation via endogenous receptors in DLD-1 cells. Phospho-specific blotting analyses revealed enhanced FAK Tyr-397 (pY397), FAK Tyr-576/Tyr-577 (pY576/pY577) as well as paxillin Tyr-31 (pY31) phosphorylation within 40 minutes of 200 nmol/L of gastrin addition to DLD-1 cells (Supplementary Fig. 2A). Increased FAK and paxillin tyrosine phosphorylation by gastrin was dependent on intrinsic FAK activity as shown by pharmacological FAK-specific PF-228 (1 μmol/L) inhibition (Fig. 2B).

Interestingly, gastrin addition to DLD-1 cells increased FA formation as detected by vinculin staining (Supplementary Fig. 2B, arrows). Gastrin also triggered the dissolution of cell–cell contacts associated with the loss of E-cadherin surface expression (Supplementary Fig. 2C). Increased paxillin staining at sites resembling FAs was detected both within the center of DLD-1 cell colonies and at peripheral

Table 1. Relative Rgnef protein expression in colon carcinoma microarray slides

<table>
<thead>
<tr>
<th>Colon tissue</th>
<th>N</th>
<th>Rgnef staining</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Negative (%)</td>
</tr>
<tr>
<td>Normal/adjacent</td>
<td>70</td>
<td>9</td>
</tr>
<tr>
<td>*Tumor grade 1–2</td>
<td>165</td>
<td>17</td>
</tr>
<tr>
<td>**Tumor grade 3–4</td>
<td>73</td>
<td>5</td>
</tr>
</tbody>
</table>

NOTE: Tissue sections from 3 commercially obtained colorectal tumor microarray slides were analyzed by immunohistochemistry and separated into three groups. Percentage of tumor sections with the indicated level of Rgnef staining (from negative to strong, ++++) are shown. N indicates total number of independent sections analyzed within group. Staining distribution and statistical significance between groups was determined by χ² tests. *, P < 0.03 compared to normal/adjacent samples; **, P < 0.0001 compared to either normal/adjacent or grade 1–2. 

Figure 1. Elevated Rgnef expression during colon cancer progression. A, schematic diagram of Rgnef (p190RhoGEF) showing locations of leucine-rich (L-rich), zinc-finger-like (Zn), Dbl/pleckstrin homology (DH/PH), and coiled-coil (C-coil) domains. Indicated is the FAK binding site (1,292–1,301) and the peptide regions used for polyclonal antibody production. B, representative colon carcinoma tumor sections stained with antibodies to Rgnef (brown) reveals increased Rgnef expression (from minimal –/– to strong ++++) as a function of tumor stage. Sections were counterstained with hematoxylin (blue). Scale bar is 0.1 mm.
sites of enhanced membrane ruffling stimulated by gastrin addition (Fig. 2C, arrows). Notably, FAK was localized in the cytoplasm of starved DLD-1 cells and exhibited enhanced FA localization upon gastrin addition (Fig. 2C). PF-228 FAK inhibition prevented gastrin-initiated FA formation (data not shown) and blocked gastrin-triggered cell scattering-motility (Supplementary Fig. 2D). Importantly, lentiviral-mediated shRNA stable knockdown of CCK2R in DLD-1 cells prevented both gastrin-triggered cell scattering and elevated paxillin tyrosine phosphorylation compared with Scr shRNA and parental DLD-1 cells (Supplementary Fig. 3). These results support the notion that gastrin promotes CCK2R-dependent FAK catalytic activation and paxillin tyrosine phosphorylation in DLD-1 cells associated with increased FA formation and the acquisition of a motile cell phenotype.

**Rgnef is in a signaling complex with FAK in colon carcinoma cells**

In fibroblasts, cell replating onto fibronectin facilitates FA formation and the recruitment of Rgnef into a signaling complex with FAK at these sites (28). In DLD-1 cells, Rgnef...
coimmunoprecipitates (co-IPs) with antibodies to FAK in starved cells and FAK co-IPs with antibodies to Rgnef (Fig. 2D). Rgnef–FAK complex formation is not altered by gastrin addition. The identity of the smaller Rgnef-immunoreactive bands associated with FAK IPs after gastrin stimulation was not determined. Notably, increased paxillin association was detected with FAK by co-IP within 30 to 60 minutes after gastrin addition (Fig. 2D). This was verified by paxillin co-IP analyses and is consistent with the notion that FAK and paxillin are recruited to newly-forming FAs upon gastrin addition. Although paxillin co-IPs with overexpressed Rgnef upon fibronectin-mediated fibroblast adhesion (28), endogenous Rgnef did not detectably co-IP with paxillin in lysates of gastrin-stimulated DLD-1 cells (Fig. 2D). These results support a model-hypothesis that gastrin triggers FA formation, FAK recruitment to these sites, and FAK-dependent paxillin tyrosine phosphorylation potentially involved in FA maturation events (39).

Rgnef knockdown reveals its importance in gastrin-stimulated paxillin tyrosine phosphorylation, cell scattering, and invasion

Although we could not detect Rgnef localization to FAs upon gastrin stimulation of DLD-1 cells (data not shown), a key role for Rgnef in gastrin-stimulated signaling was revealed through the analysis of stable knockdown DLD-1 cells (Fig. 3).
Lentiviral-mediated shRNA expression was used to individually knockdown Rgnef, FAK, c-Src, and paxillin in DLD-1 cells and more than 80% stable reduction in target protein expression was achieved (Fig. 3A). Interestingly, in FAK, c-Src, and paxillin shRNA-expressing cells, elevated expression of cYes tyrosine kinase was detected (Fig. 3A) and increased Hic-5 expression was detected in paxillin shRNA cells (data not shown). Despite potential compensatory changes associated with stable shRNA expression, Rgnef and FAK knockdown significantly prevented cell scattering upon gastrin addition compared with scrambled (Scr) shRNA DLD-1 controls (Fig. 3B and C). Paxillin and c-Src knockdown did not significantly affect gastrin-stimulated cell scattering and it was unclear whether this was associated with compensatory cell alterations. Importantly, knockdown of either Rgnef or FAK prevented gastrin-stimulated paxillin tyrosine phosphorylation, thus reinforcing the importance of the Rgnef-FAK signaling complex (Fig. 3D).

As previous studies showed that gastrin promoted colon carcinoma protease secretion and invasion (40, 41) and that FA formation can be a precursor to invadopodia formation (42), Rgnef and FAK shRNA-expressing DLD-1 cells were evaluated in an in situ gelatin zymography–cell invasion activity assay (Fig. 4). Knockdown of FAK or Rgnef significantly reduced gastrin-induced gelatin degradation activity (visualized as cell-associated dark spots) compared with Scr shRNA-expressing DLD-1 cells (Fig. 4A and B). Therefore, gastrin-stimulated cell spreading was correlated with the transition to an invasive cell phenotype. To establish a direct link between Rgnef and cell invasion, a GFP-Rgnef fusion protein was stably overexpressed in DLD-1 cells (Fig. 4C). GFP-Rgnef overexpression significantly increased cell scattering-motility and gelatin degradation activity compared with GFP-DLD-1 cells (Fig. 4C and D). Together, these results show that both Rgnef and FAK expression are required for gastrin-stimulated DLD-1 cell motility and the generation of an invasive cell phenotype.

Blocking Rgnef-FAK interaction prevents gastrin-stimulated paxillin tyrosine phosphorylation and cell scattering

To test the importance of Rgnef-FAK signaling complex in mediating gastrin signaling, the Rgnef C-terminal domain (Rgnef-C, residues 1,279–1,582) or Rgnef-C lacking the FAK binding site (Rgnef-C ΔFAK, residues 1,302–1,582) were stably overexpressed in DLD-1 cells as mCherry fusion proteins (Fig. 5A). Rgnef-C constitutively bound to FAK and disrupted the association with endogenous Rgnef, whereas Rgnef-C ΔFAK expression did not effect FAK–Rgnef association (Fig. 5A). Importantly, Rgnef-C...
but not Rgnef-CΔFAK prevented gastrin-stimulated paxillin tyrosine phosphorylation (Fig. 5B) and blocked gastrin-initiated cell scattering (Fig. 5C and D). These results support the notion that Rgnef-C acts as a dominant-negative inhibitor of the endogenous Rgnef–FAK signaling complex.

**Rgnef-C inhibits DLD-1 orthotopic tumor growth and invasion**

Prior to evaluating the tumor growth characteristics of Rgnef-C DLD-1 cells, equivalent expression of mCherry Rgnef-C and mCherry Rgnef-CΔFAK was confirmed by flow cytometry and no significant cell growth differences either under adherent or suspended conditions were observed (Supplementary Fig. 4). One million mCherry-labeled DLD-1 cells were injected into the distal posterior rectum of nude mice and allowed to grow as orthotopic tumors (Fig. 6). After 24 days, the peritoneal cavity was opened and fluorescent tumors visualized prior to and after surgical resection (Supplementary Fig. 5). Interestingly, mCherry DLD-1 and mCherry Rgnef-CΔFAK tumors were difficult to completely remove as they had become locally invasive into the distal posterior musculature of the mice. In contrast, mCherry Rgnef-C DLD-1...
tumors were primarily localized to the colon surface and were readily surgically removed (Supplementary Fig. 5).

Rgnef-C but not Rgnef-CΔFAK expression significantly inhibited DLD-1 tumor growth in vivo (Fig. 6A), despite underestimating excised tumor size due to local tumor invasion. Analysis of tumor cell lysates by immunoblotting showed that paxillin tyrosine phosphorylation was significantly inhibited in Rgnef-C but not Rgnef-CΔFAK tumors compared with DLD-1 controls (Fig. 6B). H&E staining of tumor sections confirmed that DLD-1 Rgnef-C tumors were at the surface of the colon muscularis propria and Rgnef-CΔFAK tumors were connected to the posterior musculature (Fig. 6C). Combined immunofluorescent staining of tumor sections for the muscle intermediate filament protein desmin (green), intrinsic mCherry fluorescence (red) for tumor cell detection, and DAPI staining (blue) for cell nuclei revealed that Rgnef-C tumors were encapsulated by host-associated cells and not detectably invasive into the muscularis propria at the colon surface (Fig. 6D). Conversely, Rgnef-CΔFAK tumor cells were extensively invading into the surrounding musculature (Fig. 6D).

Together, our results support the conclusion that Rgnef binding to FAK plays important roles in promoting both gastrin-stimulated DLD-1 cell motility in vitro and tumor progression in vivo associated with the regulation of paxillin tyrosine phosphorylation.

Discussion

Epithelial cancer cells metastasize in a series of linked, sequential steps initiated by extracellular matrix remodeling followed by local tumor invasion. Elucidation of the molecular processes contributing to an invasive cell phenotype is critical to understanding tumor cell metastasis. In this study, we have identified a new role for Rgnef within colon cancer cells in facilitating FAK-associated paxillin tyrosine phosphorylation initiated by gastrin and dependent on CCK2R expression. There is a growing body of literature implicating FAK signaling in cancer (13).
factors such as Eps8 elevate FAK expression (43) and tyrosine phosphorylation of proteins such as FAK and paxillin are correlated with an invasive cell phenotype (44, 45). The molecular pathways connecting GPCRs to FAK activation remain undefined. A canonical pathway for gastrin and GPCR-mediated FAK activation is likely to involve Gz12/Gz13 proteins leading to RhoA GTP binding, Rho-kinase activation, myosin light chain phosphorylation, actin stress fiber formation, and FA assembly triggering integrin clustering leading to FAK-associated paxillin phosphorylation (19). Where Rgnef fits into this pathway is unclear. However, our results support the conclusion that Rgnef may be a key RhoGEF controlling RhoA GTP binding as shRNA knock-down (Figs. 3 and 4) or dominant-negative Rgnef expression (Fig. 5) prevented gastrin-initiated cell–cell dissociation, FA formation (data not shown), and FAK-associated signaling as measured by paxillin tyrosine phosphorylation. The fact that Rgnef and FAK form a complex in quiescent DLD-1 colon carcinoma cells prior to gastrin-initiated FA formation (Fig. 2) suggests that an Rgnef-FAK signaling complex may coordinate or localize RhoA activation and FA formation in response to gastrin. This role is consistent with Rgnef function in normal fibroblasts as an important regulator of RhoA, FA formation, and motility downstream of integrins (28).

Although RhoA activation has been implicated in colorectal tumor progression (46) and active RhoA is localized to podosomes or invadopodia (35), very little is known about the key regulators contributing to elevated RhoA signaling in colon cancer. Our results using the Rgnef C-terminal domain as a dominant-negative inhibitor blocking the formation of a Rgnef-FAK signaling complex reveal that a direct binding interaction with FAK is important in regulating gastrin-stimulated paxillin phosphorylation, cell motility, and DLD-1 tumor progression (Figs. 5 and 6). Interestingly, Rgnef-C expression did not affect tumor cell proliferation in vitro, but inhibited orthotopic tumor growth in nude mice implicating a role for modulation of the tumor microenvironment. This dominant-negative effect was lost upon deletion of the FAK binding site in Rgnef-C. Although how Rgnef-C limits tumor growth in vivo remains unclear, Rgnef-C expression resulted in lower levels of tumor-associated paxillin tyrosine phosphorylation and less invasive tumors (Fig. 6). As paxillin tyrosine phosphorylation is increased upon epithelial to mesenchymal transitions in normal cells (47), involved in the assembly of FAs (12, 39), and has been correlated with tumor invasion (48), our in vitro and in vivo results are consistent with the hypothesis that Rgnef-C blocks a FAK-paxillin motility and invasion signaling pathway.

To date, the best characterized GEFs involved in colon cancer are the adenomatous polyposis coli-associated proteins Asef1-Asef2 involved in promoting Rac1 and Cdc42 activation and knockout studies have revealed their importance in promoting tumor progression (49). RhoA regulation is also important in promoting tumor spread (46), but the GEFs controlling this pathway remain undefined. Our findings that Rgnef mRNA and protein levels are elevated as a function of colon carcinoma tumor progression add important biological relevance to our mechanistic studies characterizing the importance of Rgnef-FAK interactions. Future studies will explore whether changes in Rgnef expression occur within other cancers and whether this parallels elevated expression of FAK/Pyk2 within tumors. In summary, our results support the importance of Rgnef-FAK signaling in promoting colorectal cancer progression and complement mouse genetic studies, showing that loss of FAK expression prevents colon cancer tumorigenesis downstream of Wnt/c-Myc signaling (50). FAK inhibitors may serve to control the invasive and metastatic properties of advanced colorectal cancers.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interests were disclosed.

Grant Support

Supported by NIH CA102310 and an American Heart Association Established Investigator Award (0540115N) to D. Schlaepfer. J-O. Nam was partially supported by a fellowship from the Korean Science Foundation (KRF-2008-357-E00007). A. Tomar was supported by an American Heart Association post-doctoral fellowship (0825166F). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1744 solely to indicate this fact.

Received August 6, 2010; revised September 27, 2010; accepted October 26, 2010; published OnlineFirst January 11, 2011.

References

Yu et al.


p190RhoGEF (Rgnef) Promotes Colon Carcinoma Tumor Progression via Interaction with Focal Adhesion Kinase

Hong-Gang Yu, Ju-Ock Nam, Nichol L. G. Miller, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-2894

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2011/01/10/0008-5472.CAN-10-2894.DC1

Cited articles
This article cites 50 articles, 21 of which you can access for free at:
http://cancerres.aacrjournals.org/content/71/2/360.full.html#ref-list-1

Citing articles
This article has been cited by 5 HighWire-hosted articles. Access the articles at:
/content/71/2/360.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.